NeuroBo Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Strategic Update

NeuroBo Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Strategic Update
Acquisition of ANA Therapeutics provides late-stage COVID-19 clinical development program with numerous key inflection points in 2021
News provided by
Share this article
BOSTON, April 15, 2021 /PRNewswire/ --
 NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuropathic and neurodegenerative diseases, today announced financial results for the year ended December 31, 2020 and provided a corporate strategic update.
"In December 2020, we significantly expanded our clinical pipeline with the acquisition of ANA Therapeutics and the addition of lead drug candidate, ANA001, a proprietary oral niclosamide formulation, currently in a 60-patient Phase 2/3 trial as a treatment for moderate to severe COVID-19," stated Richard J. Kang, Ph.D., President and Chief Executive Officer of NeuroBo. "The recent approval of the Contingent Value Rights (CVR) Agreement amendment from a majority of the company's CVR holders incentivizes our evaluation of Gemcabene as a treatment for COVID-19 and expands our pipeline in this indication of continued urgent need. We have a series of potentially value creating milestones over the next twelve months related to our development programs to treat COVID-19. Regarding our Phase 2 trial for ANA001, we expect to report the data monitoring committee safety results, pharmacokinetic (PK) data and the top-line data readout. We also look forward to releasing preclinical

Related Keywords

Boston ,Massachusetts ,United States ,Richardj Kang ,Michael Miller ,Contract Research Organization ,Drug Administration ,Neurobo Pharmaceuticals ,Rx Communications Group ,Nasdaq ,Prnewswire Neurobo Pharmaceuticals Inc ,Neurobo Pharmaceuticals Inc ,Development Expenses ,Exchange Commission ,Development Rd Expenses ,Gemphire Therapeutics Inc ,Therapeutics Inc ,Securities Exchange ,Chief Executive Officer ,Contingent Value Rights ,Investigational New Drug ,Operating Results ,Gemphire Therapeutics ,In Process Research ,Administrative Expenses ,Cash Equivalents ,Private Securities Litigation Reform Act ,Securities Exchange Act ,Annual Report ,Year Ended ,போஸ்டன் ,மாசசூசெட்ஸ் ,ஒன்றுபட்டது மாநிலங்களில் ,மைக்கேல் மில்லர் ,ஒப்பந்த ஆராய்ச்சி ஆர்கநைஸேஶந் ,ர்க்ஸ் தகவல்தொடர்புகள் குழு ,நாஸ்டாக் ,வளர்ச்சி செலவுகள் ,பரிமாற்றம் தரகு ,வளர்ச்சி ர்ட் செலவுகள் ,சிகிச்சை இன்க் ,பத்திரங்கள் பரிமாற்றம் ,தலைமை நிர்வாகி அதிகாரி ,தொடர்ந்து மதிப்பு உரிமைகள் ,இயங்குகிறது முடிவுகள் ,இல் ப்ரோஸெஸ் ஆராய்ச்சி ,ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் ,பத்திரங்கள் பரிமாற்றம் நாடகம் ,ஆண்டு அறிக்கை ,